Articles by tag: pancreatic-cancer

RNA vaccine against pancreatic cancer: breakthrough 2025

Chinese mRNA vaccine iNeo-Vac-R01 suppresses metastases. Analysis of efficacy, cost, and risks. Find out who will benefit from the new therapy.

Oncolytic Virotherapy of Pancreatic Cancer: Successes The Lancet

Analysis of the First Phase of Trials of an Oncolytic Virus Against Pancreatic Adenocarcinoma: The Lancet Data, Risks, Forecasts and What Was Not Written in the News. Read.

Genetically modified virus stopped pancreatic cancer: breakthrough

Oncolytic adenovirus from the University of Minnesota halted tumor growth in three patients with pancreatic cancer. Learn about the mechanism, risks, and prognosis.

MIT nanoparticles for immunotherapy of pancreatic cancer metastases

MIT scientists have created nanoparticles with AND logic for targeted activation of the STING pathway in metastases. Preclinical data: 70% reduction in metastases. Learn about the breakthrough in nanomedicine.

NEJM publishes NAPOLI-3: new standard of care for pancreatic cancer

Analysis of the NAPOLI-3 trial: NALIRIFOX regimen for metastatic pancreatic cancer. Real survival numbers, toxicity, and paradigm shift in dosing. Read more.

Paricalcitol in metastatic cancer: 2026 data

2026 clinical data confirmed the safety of the vitamin D analog paricalcitol in metastatic pancreatic cancer. Learn about the mechanism, results, and limitations.

Vitamin D analog paricalcitol against pancreatic cancer: efficacy

Paricalcitol with chemotherapy improved progression-free survival in pancreatic cancer in a phase 1 study. Analysis of Nature Cancer data. Read.

AI triples pancreatic cancer detection: REDMOD model

Mayo Clinic model finds pancreatic cancer 475 days before diagnosis on routine CT scans. Learn how AI is changing screening and survival. Read details.

AI triples sensitivity of early pancreatic cancer detection

Mayo Clinic's REDMOD model detects pancreatic cancer 475 days before diagnosis with 73% sensitivity. Learn how AI is changing oncology and who needs screening now.

Dubodencel Fast Track: treatment of glioblastoma and pancreatic cancer

Learn how dubodencel received its third Fast Track status from the FDA for treating glioblastoma, pancreatic cancer, and melanoma. Analysis of the dual-loading dendritic cell platform and prospects for patients.